COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02468726
Recruitment Status : Completed
First Posted : June 11, 2015
Last Update Posted : June 11, 2015
Information provided by (Responsible Party):

Brief Summary:

In order for flexible sigmoidoscopy to be a successful screening procedure, the bowel must be free of solid matter so the endoscopist has a clear view, increasing the chance of detection of abnormalities. This is achieved through the use of bowel cleansing preparations, which are administered prior to the procedure. Enemas are the preferred method as they clear the lower bowel more quickly than oral formulations and do not require dietary restrictions.

The medical device being tested in this clinical investigation is NER1008, an enema which contains PEG3350 (polyethylene glycol 3350). PEG3350 is an osmotic agent, which holds the water content in the rectum and sigmoid colon, consequently increasing stool volume, resulting in rectal distension and subsequent distal colon emptying. The increased colonic luminal content stimulates the motility, propulsive transportation and rectal evacuation of the distal colon content.

This study is designed to assess the performance of NER1008 in bowel cleansing and compare this with the performance of Fleet® enema, which is widely used for this purpose.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Device: NER1008 enema Drug: Fleet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Screening
Official Title: A Clinical Investigation to Demonstrate the Performance of NER1008 Enema in Bowel Cleansing Compared to Fleet® Enema
Study Start Date : November 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NER1008
Use of NER1008 enema for bowel cleansing
Device: NER1008 enema
NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy

Active Comparator: Fleet
Use of Fleet enema for bowel cleansing
Drug: Fleet
Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy

Primary Outcome Measures :
  1. Success of bowel cleansing [ Time Frame: Up to 3 hours ]
    Whether recto-sigmoid bowel cleansing has been successful, based on an endoscopist's assessment of the quality of cleansing in the rectum and colon, according to the modified Harefield cleansing scale.

Secondary Outcome Measures :
  1. Grade of bowel cleansing [ Time Frame: Up to 3 hours ]
    Grade of bowel cleansing (A, B, C or D), based on an endoscopist's assessment.

  2. Quality of cleansing in rectum [ Time Frame: Up to 3 hours ]
    Quality of cleansing in the rectum based on the modified Harefield cleansing scale (0-4).

  3. Quality of cleansing in sigmoid colon [ Time Frame: Up to 3 hours ]
    Quality of cleansing in the sigmoid colon based on the modified Harefield cleansing scale (0-4)

  4. Quality of cleansing in the descending colon [ Time Frame: Up to 3 hours ]
    Quality of cleansing in the descending colon to the splenic flexure based on the modified Harefield cleansing scale (0-4)

  5. Depth of scope progression [ Time Frame: Up to 3 hours ]
    Prior to removing the endoscope, the depth of progression it has made, in cms

  6. Stool weight [ Time Frame: Up to 3 hours ]
    Weight of stool during the one hour period after the administration of the enema

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male or female subjects [as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead electrocardiograms (ECG's) at screening] aged 18 to 45 years.
  2. Non-smokers from 3 months before enema administration and for the duration of the clinical investigation.
  3. Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2.
  4. Must voluntarily provide written informed consent to participate in the clinical investigation.
  5. Must understand the purposes and risks of the clinical investigation and agree to follow the restrictions and schedule of procedures as defined in the clinical investigation plan, and as confirmed during the informed consent process.
  6. Female subjects must be postmenopausal (for at least one year and confirmed by a serum follicle stimulating hormone (FSH) test at screening), surgically sterile, practising true sexual abstinence or must use an effective method of contraception.
  7. Female subjects of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in of each period.
  8. The subject's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical investigation.
  9. Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).

Exclusion Criteria:

  1. Subjects with a history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
  2. Subjects with a history or presence of organic or functional gastrointestinal conditions (e.g. chronic constipation, irritable bowel syndrome, inflammatory bowel disease).
  3. Subjects with a clinically relevant history or presence of abnormal gastrointestinal motility.
  4. Subjects with a significant history of hereditary bowel disorders.
  5. Subjects with abnormal findings on the digital rectal examination performed at screening.
  6. Use of laxatives or motility altering drugs in the 3 months preceding enema administration.
  7. Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 14 days prior to enema administration (or within 5 half lives if longer), with the exception of Investigator-approved hormonal contraceptives, hormone replacement therapy (HRT) and occasional paracetamol.
  8. Participation in a clinical drug study during the 30 days preceding enema administration in this clinical investigation.
  9. Donation of blood or blood products within 30 days prior to enema administration or during the clinical investigation, except as required for this clinical investigation
  10. Pregnant or lactating females.
  11. Any clinically significant illness within 28 days prior to enema administration.
  12. History or presence of any significant drug allergy, or a known allergy or contraindication to polyethylene glycols, Fleet® enema or midazolam.
  13. Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Medical Representative and Principal Investigator.
  14. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  15. Current or history of drug or alcohol abuse within the 12 months prior to enema administration, or a positive drugs of abuse test at screening or check-in.
  16. Consumption of alcoholic beverages within 24 hours of confinement or during confinement.
  17. Subjects who, in the opinion of the Investigator, are unsuitable for participation in the clinical investigation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02468726

Layout table for location information
United Kingdom
BioKinetic Europe Ltd
Belfast, United Kingdom, BT2 7BA
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: David J Bell, MD BioKinetic Europe Ltd
Layout table for additonal information
Responsible Party: Norgine Identifier: NCT02468726    
Other Study ID Numbers: NER1008-01/2011 (ENE)
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: June 11, 2015
Last Verified: November 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases